文献速递高血压

低剂量三联固定复方制剂与高血压治疗惰性及处方模式的关系:TRIUMPH试验二次分析

Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.
PubMed 文献 · JAMA Cardiol · 2020-01-01

该研究为TRIUMPH随机临床试验的事后分析,纳入700例轻中度高血压患者,比较每日一次三联固定复方制剂(替米沙坦20mg、氨氯地平2.5mg、氯噻酮12.5mg)与常规治疗。结果显示,三联复方组在未达血压目标者中治疗惰性更常见(第6周86.8% vs 63.9%,P<.001;第12周90% vs 64.8%,P<.001),但处方模式显著简化,6个月血压达标率更高(69.5% vs 55.3%)。

要点

  • 三联固定复方组治疗惰性高于常规组,但处方模式更简化。
  • 三联固定复方组6个月血压达标率更高(69.5% vs 55.3%)。
  • 随访中诊室收缩压是治疗强化的唯一一致预测因素。

核心结论

  • 三联固定复方制剂与更高的治疗惰性相关,但显著简化处方模式并改善6个月血压控制率。

研究设计与样本

  • TRIUMPH随机临床试验的事后分析,纳入700例轻中度高血压患者,来自斯里兰卡11家城市医院诊所,随访至2017年10月。

主要发现

  • 在未达血压目标者中,三联复方组治疗惰性在第6周为86.8%(92/106)vs 常规组63.9%(124/194),P<.001;第12周为90%(81/90)vs 64.8%(116/179),P<.001。
  • 研究结束时三联复方组69.5%(221/318)和常规组55.3%(182/329)达到血压目标。
  • 在接受治疗强化的患者中,基线时估计方案效力增加三联复方组为15(6)mmHg,常规组为10(5)mmHg,P<.001;第6周和第12周无显著差异。
  • 随访期间每100例接受治疗患者中,三联复方组与常规组分别有23 vs 54种独特治疗方案,P<.001。
  • 诊室收缩压水平是随访期间治疗强化的唯一一致预测因素。

临床怎么用

  • 三联固定复方制剂可简化高血压处方并提高短期血压达标率,但需关注未达标患者的治疗惰性。
  • 对初始固定复方治疗后未达标者,应积极强化治疗以进一步改善血压控制。

局限性

  • 本研究为事后分析,结果需谨慎解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fixed-dose combination (FDC) therapies are being increasingly recommended for initial or early management of patients with hypertension, as they reduce treatment complexity and potentially reduce therapeutic inertia. OBJECTIVE: To investigate the association of antihypertensive triple drug FDC therapy with therapeutic inertia and prescribing patterns compared with usual care. DESIGN, SETTING, AND PARTICIPANTS: A post hoc analysis of the Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension (TRIUMPH) study, a randomized clinical trial of 700 patients with hypertension, was conducted. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017. Data were analyzed from September to November 2019. INTERVENTIONS: Once-daily FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) or usual care. MAIN OUTCOMES AND MEASURES: Therapeutic inertia, defined as not intensifying therapy in those with blood pressure (BP) above target, was assessed at baseline and during follow-up visits. Prescribing patterns were characterized by BP-lowering drug class and treatment regimen potency. Predictors of therapeutic inertia were assessed with binomial logistic regression. RESULTS: Of the 700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years. Among patients who did not reach the BP target, therapeutic inertia was more common in the triple pill group compared with the usual care group at the week 6 visit (92 of 106 [86.8%] vs 124 of 194 [63.9%]; P < .001) and week 12 visit (81 of 90 [90%] vs 116 of 179 [64.8%]; P < .001). At the end of the study, 221 of 318 patients in the triple pill group (69.5%) and 182 of 329 patients in the usual care group (55.3%) reached BP targets. Among those who received treatment intensification, the increase in estimated regimen potency was greater in the triple pill group compared with the usual care group at baseline (predicted mean [SD] increase in regimen potency: triple pill, 15 [6] mm Hg; usual care, 10 [5] mm Hg; P < .001), whereas there were no significant differences at the week 6 or at week 12 visit. Clinic systolic BP level was the only consistent predictor of treatment intensification during follow-up. During follow-up, there were 23 vs 54 unique treatment regimens per 100 treated patients in the triple pill vs usual care groups, respectively (P < .001). CONCLUSIONS AND RELEVANCE: Triple pill FDC therapy was associated with greater rates of therapeutic inertia compared with usual care. Despite this, triple pill FDC therapy substantially simplified prescribing patterns and improved 6-month BP control rates compared with usual care. Further improvements in hypertension control could be achieved by addressing therapeutic inertia among the minority of patients who do not achieve BP control after initial FDC therapy. TRIAL REGISTRATION: ANZCTR Identifier: ACTRN12612001120864.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Wang N, Salam A, Webster R, et al. Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial. JAMA Cardiol. 2020. PMID: 32717045. doi:10.1001/jamacardio.2020.2739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。